Trial Profile
A randomised phase II study of pemetrexed compared to pemetrexed-carboplatin in pretreated patients with advanced NSCLC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2016
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Acronyms NVALT-7
- 06 Apr 2016 Results (pooled analysis of NVALT-7 and GOIRC02-2006 studies, n = 390) published in the Annals of Oncology.
- 07 Jul 2011 Pooled analysis results assessing overall survival outcomes presented at the 14th World Conference on Lung Cancer.
- 07 Jun 2011 Pooled analysis results assessing overall survival presented at the 47th Annual Meeting of the American Society of Clinical Oncology.